EMC
MCID: EPT010
MIFTS: 53

Epithelial-Myoepithelial Carcinoma (EMC)

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Epithelial-Myoepithelial Carcinoma

MalaCards integrated aliases for Epithelial-Myoepithelial Carcinoma:

Name: Epithelial-Myoepithelial Carcinoma 12 74 52 29 15 39 71
Clear Cell Adenoma 52 71
Epithelial Myoepithelial Carcinoma 52
Glycogen-Rich Adenocarcinoma 52
Monomorphic Clear Cell Tumor 52
Adenocarcinoma, Clear Cell 71
Glycogen-Rich Adenoma 52
Tubular Solid Adenoma 52
Adenomyo-Epithelioma 52
Clear Cell Carcinoma 52
Emc 52

Classifications:



External Ids:

Disease Ontology 12 DOID:5309
NCIt 49 C4199
SNOMED-CT 67 9618003
UMLS 71 C0206681 C0334315 C0334392

Summaries for Epithelial-Myoepithelial Carcinoma

MalaCards based summary : Epithelial-Myoepithelial Carcinoma, also known as clear cell adenoma, is related to chondrosarcoma, extraskeletal myxoid and endometrial clear cell adenocarcinoma. An important gene associated with Epithelial-Myoepithelial Carcinoma is NR4A3 (Nuclear Receptor Subfamily 4 Group A Member 3), and among its related pathways/superpathways are Cytoskeletal Signaling and Interleukin-4 and 13 signaling. The drugs Lenograstim and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and ovary, and related phenotypes are Increased proliferation and growth/size/body region

Wikipedia : 74 Epithelial-myoepithelial carcinoma (EMCa) is a rare malignant tumour that typically arises in a salivary... more...

Related Diseases for Epithelial-Myoepithelial Carcinoma

Diseases related to Epithelial-Myoepithelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 623)
# Related Disease Score Top Affiliating Genes
1 chondrosarcoma, extraskeletal myxoid 33.2 SMARCB1 PLAG1 NR4A3
2 endometrial clear cell adenocarcinoma 32.8 TP53 KRT7
3 clear cell renal cell carcinoma 32.2 VIM TP53 PLIN2 MUC1 KRT7
4 adenoma 30.9 TP53 PLAG1 MUC1 KRT7
5 polymorphous low-grade adenocarcinoma 30.7 VIM TP63 MUC1 ACTC1
6 angiomyolipoma 30.7 VIM KRT7 ACTC1
7 pleomorphic adenoma carcinoma 30.6 TP53 PLAG1 HMGA2
8 appendix adenocarcinoma 30.6 KRT7 HRAS
9 hemangiopericytoma, malignant 30.6 VIM MUC1 ACTC1
10 serous cystadenocarcinoma 30.6 TP53 HRAS FBXW7
11 leiomyoma 30.6 VIM HMGA2 ACTC1
12 oncocytoma 30.6 VIM MUC1 KRT7 KRT14
13 lymphangiectasis 30.5 VIM ACTC1
14 krukenberg carcinoma 30.5 MUC1 KRT7
15 neuroendocrine carcinoma 30.4 TP63 MUC1 KRT7
16 nephrogenic adenoma 30.4 TP63 MUC1 KRT7
17 sebaceous adenocarcinoma 30.4 TP53 PLIN2 KRT14
18 endometrioid ovary carcinoma 30.4 TP53 HRAS
19 salivary gland carcinoma 30.4 TP53 PLAG1 KRT7
20 breast fibroadenoma 30.3 TP53 KRT14 HMGA2
21 renal oncocytoma 30.3 VIM KRT7 KRT14
22 endometrial adenocarcinoma 30.3 VIM TP53 MUC1 KRT7
23 metanephric adenoma 30.3 VIM MUC1 KRT7
24 spindle cell sarcoma 30.3 VIM MUC1 KRT7 ACTC1
25 chromophobe renal cell carcinoma 30.2 VIM MUC1 KRT7
26 adenofibroma 30.2 VIM TP53 MUC1 KRT7 ACTC1
27 large cell carcinoma 30.2 TP63 MUC1 KRT7 HRAS
28 reticulum cell sarcoma 30.2 VIM MUC1 ACTC1
29 neurofibroma 30.2 VIM TP53 MUC1 ACTC1
30 perivascular epithelioid cell tumor 30.2 VIM MUC1 ACTC1
31 meningioma, radiation-induced 30.1 VIM SMARCB1 MUC1
32 transitional cell carcinoma 30.1 TP63 TP53 KRT7 HRAS
33 mucoepidermoid carcinoma 30.1 TP63 TP53 MUC1 KRT7 KRT14 ACTC1
34 in situ carcinoma 30.1 TP53 MUC1 KRT14 HRAS
35 adenosquamous carcinoma 30.1 TP63 TP53 MUC1 KRT7
36 rhabdoid meningioma 30.1 VIM SMARCB1
37 papillary adenocarcinoma 30.1 VIM TP53 MUC1 KRT7
38 secretory meningioma 30.0 VIM MUC1 KRT7
39 apocrine adenocarcinoma 30.0 MUC1 KRT7 KRT14
40 small cell carcinoma 30.0 TP53 MUC1 KRT7
41 sex cord-gonadal stromal tumor 30.0 VIM MUC1 KRT7
42 collecting duct carcinoma 30.0 VIM SMARCB1 MUC1 KRT7
43 hemangioma 30.0 TP53 MUC1 KRT7 ACTC1
44 squamous cell papilloma 30.0 TP53 KRT14 HRAS
45 thymic carcinoma 30.0 TP63 TP53 MUC1 KRT7
46 mucinous adenocarcinoma 30.0 VIM TP53 MUC1 KRT7
47 rhabdomyosarcoma 29.9 VIM TP53 HRAS ACTC1
48 fibroma 29.9 VIM KRT7 KRT14 ACTC1
49 myxoid chondrosarcoma 29.9 SMARCB1 NR4A3 MUC1
50 ductal carcinoma in situ 29.9 TP53 MUC1 KRT14

Graphical network of the top 20 diseases related to Epithelial-Myoepithelial Carcinoma:



Diseases related to Epithelial-Myoepithelial Carcinoma

Symptoms & Phenotypes for Epithelial-Myoepithelial Carcinoma

GenomeRNAi Phenotypes related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 SMARCB1 TP53

MGI Mouse Phenotypes related to Epithelial-Myoepithelial Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.06 ACTC1 FBXW7 HRAS KRT14 NR4A3 PLAG1
2 homeostasis/metabolism MP:0005376 10.03 ACTC1 FBXW7 HRAS KRT14 KRT7 NR4A3
3 endocrine/exocrine gland MP:0005379 9.97 FBXW7 HRAS KRT14 NR4A3 PLAG1 PLIN2
4 integument MP:0010771 9.81 FBXW7 HRAS KRT14 NR4A3 PLIN1 PLIN2
5 neoplasm MP:0002006 9.5 FBXW7 HRAS KRT14 NR4A3 SMARCB1 TP53
6 vision/eye MP:0005391 9.23 FBXW7 KRT14 PLAG1 PLIN2 SMARCB1 TP53

Drugs & Therapeutics for Epithelial-Myoepithelial Carcinoma

Drugs for Epithelial-Myoepithelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Epirubicin Approved Phase 3 56420-45-2 41867
3
Pembrolizumab Approved Phase 3 1374853-91-4
4
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
5
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
6
Gemcitabine Approved Phase 3 95058-81-4 60750
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
9
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
10
Olaparib Approved Phase 3 763113-22-0 23725625
11
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
12
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
13
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
14
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
15
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
16
Cediranib Investigational Phase 3 288383-20-0 9933475
17
Maleic acid Experimental, Investigational Phase 3 110-17-8, 110-16-7 444972
18 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
19 Adjuvants, Immunologic Phase 3
20 topoisomerase I inhibitors Phase 2, Phase 3
21 Trace Elements Phase 3
22 Micronutrients Phase 3
23 Carotenoids Phase 3
24 Albumin-Bound Paclitaxel Phase 3
25 Protein Kinase Inhibitors Phase 3
26 Anti-Infective Agents Phase 3
27 Antiviral Agents Phase 3
28 Antimetabolites Phase 3
29 Immunosuppressive Agents Phase 3
30 Antimitotic Agents Phase 3
31 Hypoglycemic Agents Phase 2, Phase 3
32 taxane Phase 3
33 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
34 Antineoplastic Agents, Immunological Phase 2, Phase 3
35 Antibodies Phase 2, Phase 3
36 Immunoglobulins Phase 2, Phase 3
37 Antibodies, Monoclonal Phase 2, Phase 3
38 Immunologic Factors Phase 2, Phase 3
39 Anti-Bacterial Agents Phase 2, Phase 3
40 Angiogenesis Inhibitors Phase 2, Phase 3
41 Antibiotics, Antitubercular Phase 2, Phase 3
42 Topoisomerase Inhibitors Phase 2, Phase 3
43
Liposomal doxorubicin Phase 2, Phase 3 31703
44 Endothelial Growth Factors Phase 2, Phase 3
45 Mitogens Phase 2, Phase 3
46 Immunoglobulin G Phase 2, Phase 3
47
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
48
Vinblastine Approved Phase 2 865-21-4 13342 241903
49
Sodium citrate Approved, Investigational Phase 2 68-04-2
50
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563

Interventional clinical trials:

(show top 50) (show all 110)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
2 A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
3 WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
4 A Randomized Trial of Adjuvant Treatment With Radiation Plus Chemotherapy Versus Radiation Alone in High Risk Endometrial Carcinoma Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5 A Randomised Trial of Lymphadenectomy and of Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer Completed NCT00003749 Phase 3
6 A Phase III Randomized Trial Comparing TAH BSO Versus TAH BSO Plus Adjuvant Pelvic Irradiation in Intermediate Risk Carcinoma of the Endometrium Completed NCT00002807 Phase 3
7 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
8 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
9 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
10 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
11 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Recruiting NCT00719303 Phase 3
12 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
13 Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy With Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3 Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
14 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
15 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
16 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
17 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
18 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
19 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
20 A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) Active, not recruiting NCT01672892 Phase 3
21 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
22 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Unknown status NCT02819596 Phase 2 Savolitinib;MEDI4736;Tremelimumab
23 Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study Unknown status NCT00226798 Phase 2 Capecitabine (Xeloda)
24 Phase II Multicenter Trial of the Austrian AGO With the Combination of Liposomal Doxorubicin (Myocet®) and Carboplatin in Primary Advanced or Metastatic and Recurrent Endometrial Cancer Unknown status NCT01100359 Phase 2 carboplatin;liposome-encapsulated doxorubicin citrate
25 A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
26 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
27 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
28 Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas Completed NCT01914510 Phase 2 ENMD-2076
29 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
30 A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum Completed NCT02315430 Phase 2 Cabozantinib S-malate
31 A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01011933 Phase 2 Selumetinib
32 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
33 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
34 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
35 Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
36 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
37 A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
38 A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer Completed NCT00688753 Phase 2 RAD001
39 A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma Completed NCT00278174 Phase 2
40 A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
41 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
42 Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma Completed NCT00455975 Phase 2 Bevacizumab
43 Phase II Study of Sunitinib in Metastatic Renal Cancer With Non-clear Cell Histology Completed NCT01034878 Phase 2 Sunitinib
44 Sorafenib Combined With Cisplatin and Gemcitabine for the Treatment of Patients With Advanced Renal Collecting Duct Carcinoma:A Pilot, Open Study Completed NCT01762150 Phase 2 Sorafenib;Gemcitabine;Cisplatin
45 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
46 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
47 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
48 A Phase II Study of Ridaforolimus in Patients With Metastatic And/Or Locally Advanced Recurrent Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
49 Phase II Trial of Paclitaxel and Carboplatin With Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
50 A Phase II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib Mesylate in Patients With Previously Treated Advanced Renal Carcinoma Completed NCT00331409 Phase 2 Everolimus;imatinib mesylate

Search NIH Clinical Center for Epithelial-Myoepithelial Carcinoma

Genetic Tests for Epithelial-Myoepithelial Carcinoma

Genetic tests related to Epithelial-Myoepithelial Carcinoma:

# Genetic test Affiliating Genes
1 Epithelial-Myoepithelial Carcinoma 29 NR4A3

Anatomical Context for Epithelial-Myoepithelial Carcinoma

MalaCards organs/tissues related to Epithelial-Myoepithelial Carcinoma:

40
Salivary Gland, Breast, Ovary, Lung, Thyroid, Kidney, Prostate

Publications for Epithelial-Myoepithelial Carcinoma

Articles related to Epithelial-Myoepithelial Carcinoma:

(show top 50) (show all 400)
# Title Authors PMID Year
1
A multicentre retrospective clinico-histopathological review of 250 patients after parotidectomy. 61
31375455 2020
2
Epithelial myoepithelial carcinoma of the parotid gland: A rare tumor with oncocytic changes. 61
32031104 2020
3
Fine-needle aspiration cytology of the apocrine variant of epithelial-myoepithelial carcinoma. 61
31433568 2020
4
Primary epithelial-myoepithelial carcinoma of the pituitary gland. 61
31900996 2020
5
Epithelial-myoepithelial carcinoma originating from a minor salivary gland in the nasal septum: A case report and literature review. 61
32000457 2020
6
Primary Cutaneous Adenomyoepithelioma Ex Spiradenoma With Malignant Histologic Features, Epithelial-Myoepithelial Carcinoma Type: A First Case Report With Molecular Studies. 61
31813296 2019
7
Utility of neck dissection for management of carcinoma of the parotid gland. 61
31564483 2019
8
Epithelial membrane antigen and DOG1 expression in minor salivary gland tumours. 61
31629156 2019
9
Primary salivary gland-type tumors of the tracheobronchial tree diagnosed by transbronchial fine needle aspiration: Clinical and cytomorphologic features with histopathologic correlation. 61
31343850 2019
10
Apocrine epithelial-myoepithelial carcinoma of the parotid gland with concurrent oncocytic change: a novel variant. 61
31078503 2019
11
Epithelial-myoepithelial carcinoma of the breast: A rare type of malignant adenomyoepithelioma. 61
31310415 2019
12
Epithelial Myoepithelial Carcinoma of Parotid Gland. 61
31741932 2019
13
A first case report of primary epithelial myoepithelial carcinoma-like renal tumor showing a perivascular pseudorosette-like pattern: Description of morphologic, immunohistochemical, and genetic features. 61
31574838 2019
14
New Insights into Tumor Heterogeneity: A Case of Solid-Oncocytic Epithelial-Myoepithelial Carcinoma of the Parotid Gland Harboring a HRAS and Heterogeneous Terminating ARID1A Mutation. 61
31309433 2019
15
Adenomyoepitheliomas of the Breast Frequently Harbor Recurrent Hotspot Mutations in PIK3-AKT Pathway-related Genes and a Subset Show Genetic Similarity to Salivary Gland Epithelial-Myoepithelial Carcinoma. 61
31094929 2019
16
Diagnostic Significance of HRAS Mutations in Epithelial-Myoepithelial Carcinomas Exhibiting a Broad Histopathologic Spectrum. 61
30994537 2019
17
Comparison of p63/p40 Expression With Myoepithelial Markers in Minor Salivary Gland Tumors. 61
30482064 2019
18
Pulmonary epithelial myoepithelial carcinoma with papillary architecture: an uncommon morphology of a rare tumour. 61
31014821 2019
19
Mammary Epithelial-Myoepithelial Carcinoma: Report of a Case With HRAS and PIK3CA Mutations by Next-Generation Sequencing. 61
30585117 2019
20
Necrotizing sialometaplasia can hide the presence of salivary gland tumors: A case series. 61
30776173 2019
21
Salivary Duct Carcinoma of the Parotid Gland Originating from an Epithelial-Myoepithelial Carcinoma: Report of a Rare Case. 61
30937832 2019
22
More than meets the eye. 61
30737321 2019
23
Immunohistochemical evaluation of salivary gland tumors differentiation and proliferation by using calponin and telomerase. 61
30705574 2019
24
Epithelial-myoepithelial carcinoma of the supraclavicular region: An unusual cause of dyspnea. 61
31909389 2019
25
Water-Clear Cell Adenoma of the Mediastinal Parathyroid Gland. 61
28832084 2019
26
Radiation-associated epithelial-myoepithelial carcinoma among five secondary malignancies: A case report and review of literature. 61
30622928 2018
27
Clinical, pathological and treatment factors associated with the survival of patients with primary pulmonary salivary gland-type tumors. 61
30527184 2018
28
Epithelial-Myoepithelial Carcinoma in a Canine Salivary Gland. 61
30502796 2018
29
Dedifferentiation of oncocytic epithelial-myoepithelial carcinoma to mucoepidermoid carcinoma in parotid gland: A rare case report. 61
30303150 2018
30
Epithelial-Myoepithelial Carcinoma Presenting as a Pseudo Veno-Lymphatic Malformation. 61
30080758 2018
31
Primary epithelial-myoepithelial carcinoma of the lung with cavitary lesion: A case report. 61
30155254 2018
32
Epithelial-myoepithelial carcinoma of the lung: a case report. 61
29987577 2018
33
Endobronchial epithelial-myoepithelial carcinoma of the lung. 61
29196470 2018
34
Epithelial Myoepithelial Carcinoma of the Nasal Cavity: Clinical, Histopathological, and Immunohistochemical Distinction of a Case Report. 61
29237344 2018
35
Metaplastic breast carcinoma composed of epithelial-myoepithelial carcinoma and squamous cell carcinoma: A case report. 61
29642184 2018
36
Inferiorly Pedicled Nasolabial Flap for Reconstruction of Anterior Maxilla Defects Class I and II. 61
29239921 2018
37
MYB Translocation Status in Salivary Gland Epithelial-Myoepithelial Carcinoma: Evaluation of Classic, Variant, and Hybrid Forms. 61
29135517 2018
38
The So-Called Aggressive Digital Papillary Adenocarcinoma Is Epithelial-Myoepithelial Carcinoma. 61
29384814 2018
39
Salivary Gland Neoplasms: Does Morphological Diversity Reflect Tumor Heterogeneity. 61
28930752 2018
40
Epithelial-myoepithelial carcinoma: a population-based survival analysis. 61
30127663 2018
41
Epithelial-Myoepithelial Carcinoma: Frequent Morphologic and Molecular Evidence of Preexisting Pleomorphic Adenoma, Common HRAS Mutations in PLAG1-intact and HMGA2-intact Cases, and Occasional TP53, FBXW7, and SMARCB1 Alterations in High-grade Cases. 61
29135520 2018
42
Sinonasal epithelial-myoepithelial carcinoma: Report of a novel subsite and review of the literature. 61
29977654 2018
43
Epithelial-myoepithelial carcinoma with high-grade transformation of parotid gland: A case report and literature review. 61
29245272 2017
44
HPV-related Multiphenotypic Sinonasal Carcinoma: An Expanded Series of 49 Cases of the Tumor Formerly Known as HPV-related Carcinoma With Adenoid Cystic Carcinoma-like Features. 61
28877065 2017
45
Primary hyperparathyroidism caused by enormous unilateral water-clear cell parathyroid hyperplasia. 61
28888222 2017
46
First case report of a curative wedge resection in epithelial-myoepithelial carcinoma of the lung. 61
28653299 2017
47
Water Clear Cell Adenoma of the Parathyroid Gland: A Forgotten Cause of Primary Hyperparathyroidism. 61
28382826 2017
48
Carcinoma Ex Pleomorphic Adenoma of the Lacrimal Gland with Epithelial-Myoepithelial Carcinoma Histologic Type. 61
26934566 2017
49
Close surgical margin after conservative parotidectomy in early stage low-/intermediate-grade parotid carcinoma: Outcome of watch and wait policy. 61
28438287 2017
50
Salivary epithelial-myoepithelial carcinoma: clinical, morphological and molecular features. 61
28635988 2017

Variations for Epithelial-Myoepithelial Carcinoma

Cosmic variations for Epithelial-Myoepithelial Carcinoma:

9 (show top 50) (show all 998)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87897883 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
2 COSM87133148 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.3145G>C p.G1049R 3:179234302-179234302 4
3 COSM87135928 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.331A>G p.K111E 3:179199156-179199156 4
4 COSM98832818 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.455T>A p.L152* 23:53217863-53217863 4
5 COSM112988925 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 4
6 COSM150915108 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
7 COSM133535772 AKT1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.49G>A p.E17K 14:104780214-104780214 4
8 COSM151592898 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
9 COSM149960989 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 4
10 COSM150962667 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 4
11 COSM151345966 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 4
12 COSM151492854 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 4
13 COSM146246972 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
14 COSM110182063 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
15 COSM151326946 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 4
16 COSM150312692 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
17 COSM105721394 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.182A>G p.Q61R 11:533874-533874 4
18 COSM102381853 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
19 COSM89233576 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.49G>A p.E17K 14:104780214-104780214 4
20 COSM145017479 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.542A>G p.Y181C 17:7674872-7674872 4
21 COSM103028523 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.455T>A p.L152* 23:53217863-53217863 4
22 COSM148933502 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.*225G>C p.? 3:179234302-179234302 4
23 COSM102453467 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
24 COSM150277642 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
25 COSM144087035 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.182A>G p.Y61C 17:7674872-7674872 4
26 COSM105584865 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.49G>A p.E17K 14:104780214-104780214 4
27 COSM93183448 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
28 COSM98760930 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.455T>A p.L152* 23:53217863-53217863 4
29 COSM103842060 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.49G>A p.E17K 14:104780214-104780214 4
30 COSM150815521 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
31 COSM150455095 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
32 COSM111758374 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
33 COSM101951686 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 4
34 COSM151309497 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
35 COSM91331243 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 4
36 COSM122271391 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.263A>G p.Y88C 17:7674872-7674872 4
37 COSM143156731 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.182A>G p.Y61C 17:7674872-7674872 4
38 COSM144650895 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.542A>G p.Y181C 17:7674872-7674872 4
39 COSM150144859 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
40 COSM106053037 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
41 COSM105620035 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
42 COSM98771857 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.332T>A p.L111* 23:53217863-53217863 4
43 COSM105721476 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 4
44 COSM151828150 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
45 COSM150092506 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 4
46 COSM105890802 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
47 COSM149483724 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
48 COSM111889541 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
49 COSM149388003 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
50 COSM111039211 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4

Expression for Epithelial-Myoepithelial Carcinoma

Search GEO for disease gene expression data for Epithelial-Myoepithelial Carcinoma.

Pathways for Epithelial-Myoepithelial Carcinoma

Pathways related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.95 VIM MUC1 KRT7 ACTC1
2 11.55 VIM TP53 MUC1
3 11.51 VIM TP63 TP53 HRAS HMGA2
4
Show member pathways
11.47 VIM KRT7 KRT14
5 10.95 TP53 HRAS FBXW7

GO Terms for Epithelial-Myoepithelial Carcinoma

Cellular components related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.7 VIM TP63 TP53 PLIN2 PLIN1 PLAG1
2 nucleus GO:0005634 9.44 VIM TP63 TP53 SMARCB1 PLIN2 PLAG1

Biological processes related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.72 VIM TP53 SMARCB1 KRT7 FBXW7
2 negative regulation of gene expression GO:0010629 9.71 TP53 PLAG1 HRAS FBXW7
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.7 TP63 TP53 SMARCB1 PLAG1 NR4A3 HRAS
4 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 TP53 MUC1
5 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.37 TP53 MUC1
6 positive regulation of histone H4 acetylation GO:0090240 9.26 SMARCB1 MUC1
7 cell aging GO:0007569 9.13 TP63 TP53 HRAS
8 positive regulation of gene expression GO:0010628 9.1 VIM TP53 PLAG1 HRAS HMGA2 ACTC1

Molecular functions related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.55 TP63 TP53 PLAG1 NR4A3 HMGA2
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.43 TP53 SMARCB1 PLAG1 NR4A3 MUC1 HMGA2
3 cAMP response element binding GO:0035497 9.37 NR4A3 HMGA2
4 MDM2/MDM4 family protein binding GO:0097371 9.32 TP63 TP53
5 keratin filament binding GO:1990254 9.26 VIM KRT14
6 p53 binding GO:0002039 8.92 TP63 TP53 SMARCB1 MUC1

Sources for Epithelial-Myoepithelial Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....